pargyline has been researched along with Parkinson Disease in 29 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The etiology of idiopathic Parkinson's disease remains as an enigma." | 2.41 | [Studies on endogenous toxins as pathogenic factors in idiopathic parkinson's disease]. ( Maruyama, W; Naoi, M, 2000) |
| "Selegiline is a monamine oxidase type B (MAO-B) inhibitor that incorporates a propargyl ring within its molecular structure." | 1.33 | Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. ( Olanow, CW, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (34.48) | 18.7374 |
| 1990's | 3 (10.34) | 18.2507 |
| 2000's | 10 (34.48) | 29.6817 |
| 2010's | 4 (13.79) | 24.3611 |
| 2020's | 2 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Rojas, RJ | 1 |
| Edmondson, DE | 1 |
| Almos, T | 1 |
| Scott, R | 1 |
| Massari, ME | 1 |
| Meiring, L | 1 |
| Petzer, JP | 1 |
| Legoabe, LJ | 1 |
| Petzer, A | 1 |
| Manoharan, A | 1 |
| Oh, JM | 1 |
| Benny, F | 1 |
| Kumar, S | 1 |
| Abdelgawad, MA | 1 |
| Ghoneim, MM | 1 |
| Shaker, ME | 1 |
| El-Sherbiny, M | 1 |
| Almohaimeed, HM | 1 |
| Gahtori, P | 1 |
| Kim, H | 1 |
| Mathew, B | 1 |
| Szkilnik, R | 1 |
| Brus, R | 1 |
| Malinowska-Borowska, J | 1 |
| Nowak, D | 1 |
| Waliczek, M | 1 |
| Kostrzewa, RM | 1 |
| Nowak, P | 1 |
| Huleatt, PB | 2 |
| Khoo, ML | 2 |
| Chua, YY | 1 |
| Tan, TW | 1 |
| Liew, RS | 1 |
| Balogh, B | 1 |
| Deme, R | 1 |
| Gölöncsér, F | 2 |
| Magyar, K | 1 |
| Sheela, DP | 1 |
| Ho, HK | 1 |
| Sperlágh, B | 2 |
| Mátyus, P | 2 |
| Chai, CL | 2 |
| Baranyi, M | 1 |
| Porceddu, PF | 1 |
| Kulcsár, S | 1 |
| Otrokocsi, L | 1 |
| Kittel, Á | 1 |
| Pinna, A | 1 |
| Frau, L | 1 |
| Dunkel, P | 1 |
| Morelli, M | 1 |
| Naoi, M | 3 |
| Maruyama, W | 3 |
| Tatton, W | 1 |
| Chalmers-Redman, R | 1 |
| Tatton, N | 1 |
| Tabakman, R | 1 |
| Lecht, S | 1 |
| Lazarovici, P | 1 |
| Jenner, P | 2 |
| Youdim, MB | 2 |
| Fridkin, M | 1 |
| Zheng, H | 1 |
| Olanow, CW | 1 |
| Dell'Antone, P | 1 |
| IbnLkayat, M | 1 |
| Drago, D | 1 |
| Zatta, P | 1 |
| Yi, H | 1 |
| Akao, Y | 1 |
| Yamaoka, Y | 1 |
| Shamoto-Nagai, M | 1 |
| Parsons, B | 2 |
| Rainbow, TC | 2 |
| Brannan, T | 1 |
| Prikhojan, A | 1 |
| Martínez-Tica, J | 1 |
| Yahr, MD | 1 |
| Matsubara, K | 1 |
| Senda, T | 1 |
| Uezono, T | 1 |
| Awaya, T | 1 |
| Ogawa, S | 1 |
| Chiba, K | 1 |
| Shimizu, K | 1 |
| Hayase, N | 1 |
| Kimura, K | 1 |
| Chacón, JN | 1 |
| Truscott, TG | 1 |
| Susel, Z | 1 |
| Yarnitsky, D | 1 |
| Parenti, M | 1 |
| Flauto, C | 1 |
| Parati, E | 1 |
| Vescovi, A | 1 |
| Groppetti, A | 1 |
| Marsden, CD | 1 |
| Finberg, JP | 1 |
| Eaker, EY | 1 |
| Bixler, GB | 1 |
| Dunn, AJ | 1 |
| Moreshead, WV | 1 |
| Mathias, JR | 1 |
| Reznikoff, G | 1 |
| Manaker, S | 1 |
| Rhodes, CH | 1 |
| Reches, A | 1 |
| Boulton, AA | 1 |
| Wu, PH | 1 |
| Gorkin, VZ | 1 |
| Dandiya, PC | 1 |
| Bhargava, LP | 1 |
7 reviews available for pargyline and Parkinson Disease
| Article | Year |
|---|---|
Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Survival; Glyceraldehyde-3-Phosphate Dehydrogen | 2003 |
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
Topics: Amphetamines; Animals; Antiparkinson Agents; Apoptosis; Clinical Trials as Topic; Drug Evaluation, P | 2004 |
[Studies on endogenous toxins as pathogenic factors in idiopathic parkinson's disease].
Topics: Aging; Animals; Apoptosis; Dopamine; Humans; Methyltransferases; Mitochondria; Neurotoxins; Pargylin | 2000 |
[Protective therapy in Parkinson's disease].
Topics: Animals; Humans; Levodopa; Pargyline; Parkinson Disease; Selegiline | 1990 |
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1986 |
Noradrenergic influences on dopaminergic function and the pharmacology of dihydroxyphenylserine (DOPS): implication for Parkinson's disease.
Topics: Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Brain; Carbidopa; Dopamine; Droxidopa; Levodop | 1985 |
[New data on monoamine oxidase inhibitors].
Topics: Acridines; Animals; Brain; Cytoplasm; Hydrazines; Iproniazid; Isoquinolines; Liver; Membranes; Mitoc | 1971 |
22 other studies available for pargyline and Parkinson Disease
| Article | Year |
|---|---|
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
Topics: Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Small Molecule Libraries | 2015 |
The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.
Topics: Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Propy | 2022 |
Assembling a Cinnamyl Pharmacophore in the C3-Position of Substituted Isatins via Microwave-Assisted Synthesis: Development of a New Class of Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease.
Topics: Antipsychotic Agents; Dopamine Agents; Humans; Isatin; Microwaves; Molecular Docking Simulation; Mon | 2023 |
Ontogenetic manganese exposure with perinatal 6-OHDA lesioning alters behavioral responses of rats to dopamine D₁ and D2 agonist treatments.
Topics: Animals; Behavior, Animal; Desipramine; Dopamine; Dopamine Agonists; Exploratory Behavior; Female; H | 2014 |
Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
Topics: Animals; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Humans; Mice; Molecular S | 2015 |
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Male; Oxidative St | 2016 |
Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.
Topics: Apoptosis; Clinical Trials as Topic; Dopamine; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibito | 2009 |
Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?
Topics: Animals; Apoptosis; Enzyme Inhibitors; Humans; Indans; Models, Chemical; Monoamine Oxidase; Monoamin | 2004 |
Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Topics: Animals; Brain; Drug Delivery Systems; In Vitro Techniques; Indans; Iron Chelating Agents; Male; Mit | 2004 |
Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease.
Topics: Clinical Trials as Topic; Evidence-Based Medicine; Humans; Indans; Neuroprotective Agents; Pargyline | 2006 |
Acidic vesicles of the endo-exocytic pathways as targets for some anti-monoamine oxidase drugs.
Topics: Acid-Base Equilibrium; Acids; Alzheimer Disease; Amantadine; Animals; Brain; Brain Chemistry; Brain | 2009 |
Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers.
Topics: Alkynes; Cell Death; Cell Line, Tumor; Energy Metabolism; Genetic Markers; Glial Cell Line-Derived N | 2007 |
High-affinity binding sites for [3H]MPTP may correspond to monamine oxidase.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Binding Sites; Brain; Monoam | 1984 |
In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dopamine; Homovanillic Acid; L | 1995 |
L-Deprenyl prevents the cell hypoxia induced by dopaminergic neurotoxins, MPP(+) and beta-carbolinium: a microdialysis study in rats.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Carbolines; Cell Hypoxia; Dopamine; Dose-Response Relationship | 2001 |
Chemically induced Parkinson's disease. III: A study of a possible role of singlet molecular oxygen in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Free Radicals; Lasers; Monoamine Oxidase; Oxygen; Parg | 1991 |
Manganese neurotoxicity: effects of L-DOPA and pargyline treatments.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Basal Ganglia Diseases; Corpus Striatum; Dopamine; Drug Syn | 1986 |
MAO type B inhibitors as adjunct to L-dopa therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkynes; Animals; Brain; Drug Therapy, Combination; Hu | 1987 |
Chronic alterations in jejunal myoelectric activity in rats due to MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catecholamines; Caudate Nucleus; Electromyogr | 1987 |
Similar distribution of monoamine oxidase (MAO) and parkinsonian toxin (MPTP) binding sites in human brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Autoradiography; Binding Sites; Brain; Humans; M | 1985 |
Effect of L-DOPA on the synthesis and excretion of tyramine.
Topics: Animals; Brain Stem; Caudate Nucleus; Cerebellum; Dopamine; Humans; Hypothalamus; Levodopa; Octopami | 1974 |
The antiparkinsonian activity of monoamine oxidase inhibitors and other agents in rats and mice.
Topics: Animals; Dextroamphetamine; Diphenhydramine; Imipramine; Iproniazid; Isocarboxazid; Mice; Monoamine | 1968 |